Caribou Biosciences, Inc. Common Stock

Day range

$0.50 – $0.54

Open

$0.53

Prev close

$0.53

Volume

1.35M

Market cap

$57.12M

Shares out

107.21M

P/E

—

P/S

5.66

P/B

0.58

P/FCF

—

ROE

-105.6%

ROA

-72.5%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Workforce reductionOct 6, 2026

  The reduction in workforce is anticipated to occur in phases with the majority of affected employees expected to depart in the fourth quarter of 2026 with a limited number of employees expected to remain through completion of the Company's process of exploring strategic alternatives to support transaction execution and business wind-down activities.

• Regulatory decisionJun 11, 2026

  As previously disclosed, the Company has reached alignment with the U.S. Food and Drug Administration (FDA) on the design of ANTLER-3, a randomized, controlled pivotal phase 3 clinical trial expected to enroll approximately 250 CD19-naïve 2L LBCL patients. The primary endpoint is PFS. The study is expected to be conducted at approximately 75 clinical trial sites globally.

• Regulatory decisionMar 31, 2026

  the Company issued a press release announcing that it received Regenerative Medicine Advanced Therapy ('RMAT') designation for relapsed or refractory multiple myeloma ('r/r MM') from the U.S. Food and Drug Administration ('FDA') for CB-011, the Company's allogeneic anti-BCMA CAR-T cell therapy product candidate.

• Investor presentationNov 3, 2025

  The Company will host a live webcast today, Monday, November 3, 2025, at 8:00 a.m. Eastern Time, to discuss the clinical developments for both vispa-cel and CB-011. A copy of the slide presentation to be used during the Company's webcast is attached hereto as Exhibit 99.3 and incorporated by reference herein.

• Business updateAug 12, 2025

  issued a press release announcing the Company's financial results for the quarter ended June 30, 2025, and providing a business update.

Days to cover

13.1

Short interest

12.91M

Avg volume

986.42K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Looking for Earnings Beat? Buy These 5 Top-Ranked Stocks
  positiveZacks Investment Research· Aug 31, 2026
• Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
  positiveGlobeNewswire Inc.· Jun 29, 2026
• Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meeting
  positiveGlobeNewswire Inc.· Jun 11, 2026
• Genome Editing Market Forecast to Reach $23.6 Billion by 2031 Registering 16.6% CAGR: Insights Into Technology and Investment Trends
  positiveGlobeNewswire Inc.· Jan 22, 2026
• Caribou Biosciences Announces Positive Data from CaMMouflage Phase 1 Trial of CB-011 in Multiple Myeloma
  positiveGlobeNewswire Inc.· Nov 3, 2025